Functional subsets of mouse natural killer cells

Immunological Reviews

Volumn 214, Issue 1, 2006, Pages 47-55

  Hayakawa, Yoshihiro ^a   Huntington, Nicholas D ^b   Nutt, Stephen L ^b   Smyth, Mark J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Chemokine; Cytokine; Cytotoxicity; Differentiation; Migration; Natural killer cell

Indexed keywords

CD27 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR; CYTOKINE RECEPTOR; NATURAL KILLER CELL RECEPTOR;

CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL HETEROGENEITY; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SUBPOPULATION; CYTOKINE PRODUCTION; CYTOTOXICITY; HOMEOSTASIS; IMMUNE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; KILLER CELLS, NATURAL; LYMPHOCYTE SUBSETS; MICE;

EID: 33750718786     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2006.00454.x     Document Type: Review

References (69)

1. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 1983;131:1789-1796.
2. Sedlmayr P, Schallhammer L, Hammer A, Wilders-Truschnig M, Wintersteiger R, Dohr G. Differential phenotypic properties of human peripheral blood CD56dim+ and CD56bright+ natural killer cell subpopulations. Int Arch Allergy Immunol 1996;110:308-313.
3. Frey M, et al. Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol 1998;161:400-408.
4. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-640.
5. Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat Rev Immunol 2003;3:413-425.
6. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 2006;176:1517-1524.
7. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004;22:405-429.
8. Raulet DH. Development and tolerance of natural killer cells. Curr Opin Immunol 1999;11:129-134.
9. Perussia B, Chen Y, Loza MJ. Peripheral NK cell phenotypes: multiple changing of faces of an adapting, developing cell. Mol Immunol 2005;42:385-395.
10. Ikawa T, Fujimoto S, Kawamoto H, Katsura Y, Yokota Y. Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. Proc Natl Acad Sci USA 2001;98:5164-5169.
11. Rosmaraki EE, Douagi I, Roth C, Colucci F, Cumano A, Di Santo JP. Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol 2001;31:1900-1909.
12. Kim S, et al. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol 2002;3:523-528.
13. Takeda K, et al. TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood 2005;105:2082-2089.
14. Watts TH. Tnf/Tnfr family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
15. van Baarle D, Kostense S, van Oers MH, Hamann D, Miedema F. Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue. Trends Immunol 2002;23:586-591.
16. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol 2005;23:487-513.
17. Hintzen RQ, de Jong R, Lens SM, van Lier RA. CD27: marker and mediator of T-cell activation? Immunol Today 1994;15:307-311.
18. Takeda K, et al. CD27-mediated activation of murine NK cells. J Immunol 2000;164:1741-1745.
19. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-274.
20. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990;11:237-244.
21. Tang A, Amagai M, Granger LG, Stanley JR, Udey MC. Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin. Nature 1993;361:82-85.
22. Grundemann C, et al. Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol 2006;176:1311-1315.
23. Ito M, Maruyama T, Saito N, Koganei S, Yamamoto K, Matsumoto N. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J Exp Med 2006;203:289-295.
24. Di Santo JP. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 2006;24:257-286.
25. Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol 2002;71:173-183.
26. Maghazachi AA. G protein-coupled receptors in natural killer cells. J Leukoc Biol 2003;74:16-24.
27. Inngjerdingen M, Damaj B, Maghazachi AA. Expression and regulation of chemokine receptors in human natural killer cells. Blood 2001;97:367-375.
28. Mack M, et al. Expression and characterization of the chemokine receptors CCR2 and CCR5 in mice. J Immunol 2001;166:4697-4704.
29. Sechler JM, Barlic J, Grivel JC, Murphy PM. IL-15 alters expression and function of the chemokine receptor CX3CR1 in human NK cells. Cell Immunol 2004;230:99-108.
30. Barlic J, Sechler JM, Murphy PM. IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1. Blood 2003;102:3494-3503.
31. Lavergne E, et al. Fractalkine mediates natural killer-dependent antitumor responses in vivo. Cancer Res 2003;63:7468-7474.
32. Huang D, et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006;20:896-905.
33. Townsend MJ, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004;20:477-494.
34. Taki S, Nakajima S, Ichikawa E, Saito T, Hida S. IFN regulatory factor-2 deficiency revealed a novel checkpoint critical for the generation of peripheral NK cells. J Immunol 2005;174:6005-6012.
35. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002;2:656-663.
36. Hayakawa Y, et al. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 2004;172:123-129.
37. Martin-Fontecha A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004;5:1260-1265.
38. Freud AG, et al. A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 2005;22:295-304.
39. Freud AG, et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006;203:1033-1043.
40. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998;188:2375-2380.
41. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-861.
42. Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 2003;18:1-6.
43. Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004;95:777-783.
44. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989;143:3183-3191.
45. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 1990;171:1509-1526.
46. Nagler A, Lanier LL, Phillips JH. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med 1990;171:1527-1533.
47. Robertson MJ, et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992;175:779-788.
48. Colonna M, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997;186:1809-1818.
49. Voss SD, Daley J, Ritz J, Robertson MJ. Participation of the CD94 receptor complex in costimulation of human natural killer cells. J Immunol 1998;160:1618-1626.
50. Cooper MA, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-3151.
51. Peritt D, Robertson S, Gri G, Showe L, Aste-Amezaga M, Trinchieri G. Differentiation of human NK cells into NK1 and NK2 subsets. J Immunol 1998;161:5821-5824.
52. Katsumoto T, et al. STAT6-dependent differentiation and production of IL-5 and IL-13 in murine NK2 cells. J Immunol 2004;173:4967-4975.
53. Salazar-Mather TP, Orange JS, Biron CA. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 1998;187:1-14.
54. Smyth MJ, Kelly JM, Baxter AG, Korner H, Sedgwick JD. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J Exp Med 1998;188:1611-1619.
55. Prlic M, Blazar BR, Farrar MA, Jameson SC. In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 2003;197:967-976.
56. Jamieson AM, Isnard P, Dorfman JR, Coles MC, Raulet DH. Turnover and proliferation of NK cells in steady state and lymphopenic conditions. J Immunol 2004;172:864-870.
57. Ogasawara K, et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998;391:700-703.
58. Cooper MA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002;100:3633-3638.
59. Kennedy MK, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000;191:771-780.
60. Ranson T, Vosshenrich CA, Corcuff E, Richard O, Muller W, Di Santo JP. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 2003;101:4887-4893.
61. Carson WE, et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997;99:937-943.
62. DiSanto JP, Keever CA, Small TN, Nicols GL, O'Reilly RJ, Flomenberg N. Absence of interleukin 2 production in a severe combined immunodeficiency disease syndrome with T cells. J Exp Med 1990;171:1697-1704.
63. Piguet PF, Grau G, Irle C, Vassalli P. Administration of recombinant interleukin 2 to mice enhances production of hemopoietic and natural killer cells. Eur J Immunol 1986;16:1257-1261.
64. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 1998;46:318-326.
65. Huntington ND, Xu Y, Nutt SL, Tarlinton DM. A requirement for CD45 distinguishes Ly49D-mediated cytokine and chemokine production from killing in primary natural killer cells. J Exp Med 2005;201:1421-1433.
66. Caligiuri MA, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993;91:123-132.
67. Fehniger TA, et al. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 2000;106:117-124.
68. Houghton AN, Scheinberg DA. Monoclonal antibody therapies - a 'constant' threat to cancer. Nat Med 2000;6:373-374.
69. Ruggeri L, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.